(VIANEWS) – Halozyme Therapeutics (HALO), Catalyst Pharmaceuticals (CPRX), Lakeland Bancorp (LBAI) are the highest sales growth and return on equity stocks on this list.

Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?

1. Halozyme Therapeutics (HALO)

101.9% sales growth and 177.35% return on equity

Halozyme Therapeutics, Inc. is a platform biopharmaceutical company that operates in the United States, Switzerland, Ireland, Belgium, Japan, as well as internationally. Products of the company are built on ENHANZE, which is a patent-pending recombinant human Hyaluronidase enzyme. This technology allows for subcutaneous delivery and administration of injectable biologics such as monoclonal antibody and therapeutic molecules. Hylenex is the company’s flagship product. It uses rHuPH20 as a subcutaneous fluid delivery technology to achieve hydration. This helps to increase dispersion of other injectable drugs and radiopaque agent resorption. Perjeta, RITUXAN HYCELA, and MabThera SC are also developed by the company. RITUXAN SC is for CLL patients; RITUXAN SC can be used for non-Hodgkin Lymphoma. HYQVIA treats immunodeficiency disorder. It is also developing Tecentriq, a non-small-cell lung cancer treatment; OCREVUS to treat multiple sclerosis; DARZALEX to treat patients with amyloidosis and smoldering meeloma; nivolumab to treat solid tumors; ARGX113, a human neonatal Fc receiver; ARGX117 for autoimmune disorders; and BMS-986179 an anti-CD73 antibody. F. Hoffmann-La Roche, Inc., Hoffmann-La Roche, Inc., Baxalta US Inc., Baxalta GmbH, Pfizer Inc., Janssen Biotech, Inc., AbbVie, Inc., Eli Lilly and Company, Bristol-Myers Squibb Company, Alexion Pharma Holding, ARGENX BVBA, Horizon Therapeutics plc, Centre for the AIDS Programme of Research, South Africa, and ViiV Healthcare Limited for small and larger molecule targets for the prevention and treatment and to treat and for HIV. Halozyme Therapeutics, Inc., was established in 1998. It is located in San Diego, California.

Earnings Per Share

As for profitability, Halozyme Therapeutics has a trailing twelve months EPS of $2.54.

PE Ratio

Halozyme Therapeutics has a trailing twelve months price to earnings ratio of 16.4. Meaning,
the purchaser of the share is investing $16.4 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 177.35%.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Halozyme Therapeutics’s EBITDA is 134.68.

Revenue Growth

Year-on-year quarterly revenue growth grew by 11.7%, now sitting on 487.48M for the twelve trailing months.

Sales Growth

Halozyme Therapeutics’s sales growth is 79.6% for the present quarter and 101.9% for the next.

Volume

Today’s last reported volume for Halozyme Therapeutics is 923861 which is 33.8% below its average volume of 1395680.

2. Catalyst Pharmaceuticals (CPRX)

54.1% sales growth and 22.59% return on equity

Catalyst Pharmaceuticals, Inc. is a biopharmaceutical firm at the commercial stage. It specializes in developing and marketing therapies for patients with neurological, debilitating, or chronic neuromuscular diseases. Firdapse is an amifampridine-phosphate tablet for patients suffering from lambert–eaton syndrome (LEMS). Ruzurgi can be used to treat LEMS children. Firdapse is also developed by the company to treat MuSK antibody positive myasthenia Gravis and spinal muscular atrophy Type 3. It can also be used to treat hereditary nervepathy with liability for pressure palsies. Endo Ventures Limited and BioMarin Pharmaceutical Inc. have license agreements. Endo Ventures Limited has a collaboration agreement for the commercialization and development of generic Sabril tablets. Catalyst Pharmaceutical Partners, Inc. was the company’s former name. It changed its name in May 2015 to Catalyst Pharmaceuticals, Inc. Catalyst Pharmaceuticals, Inc., was established in 2002. It is located in Coral Gables, Florida.

Earnings Per Share

As for profitability, Catalyst Pharmaceuticals has a trailing twelve months EPS of $0.71.

PE Ratio

Catalyst Pharmaceuticals has a trailing twelve months price to earnings ratio of 17.3. Meaning,
the purchaser of the share is investing $17.3 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 22.59%.

Growth Estimates Quarters

The company’s growth estimates for the present quarter and the next is 54.5% and 80%, respectively.

3. Lakeland Bancorp (LBAI)

35% sales growth and 9.49% return on equity

Lakeland Bancorp, Inc. is the bank holding firm for Lakeland Bank. It offers a variety of banking services and products for small and medium-sized businesses as well as individual customers. It offers various banking services including time, savings and money market accounts as well demand deposits. The company also offers consumer banking services, including checking, savings, money market, certificates, certificates of deposits, secured and unsecure loans, consumer loans, mortgage loans and safe deposit services. The company also offers non-deposit services such as investment advisory services. These include mutual funds, variable annuities and securities brokerage. There are 48 branches in Bergen, Essex and Morris counties, as well as six regional New Jersey commercial lending centers located in Bernardsville and Iselin. Montville, Teaneck and Teaneck. One commercial lending center is also available in New York for the Hudson Valley. Oak Ridge is the company’s headquarters.

Earnings Per Share

As for profitability, Lakeland Bancorp has a trailing twelve months EPS of $1.34.

PE Ratio

Lakeland Bancorp has a trailing twelve months price to earnings ratio of 12.28. Meaning,
the purchaser of the share is investing $12.28 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 9.49%.

4. First Western Financial (MYFW)

29.4% sales growth and 9.26% return on equity

First Western Financial, Inc., is a financial holding firm that provides wealth management, private bank, personal trust, investment, mortgage lending, and other services. Two segments of the company are Wealth Management and Mortgage. Wealth Management provides investment advisory services and products for deposit, loan and insurance. The mortgage segment is responsible for soliciting, initiating, and selling secondary mortgage loans. The company serves professionals, entrepreneurs, families with high net worth, as well as philanthropic or business groups. It operates 15 profit centres, which include 11 private trust banks with 2 locations each in Arizona and 8 in Colorado and 1 in Wyoming; 2 loan production office locations with 1 in Ft. Collins and 1 in Greenwood Village in Colorado; and 2 trust and trust offices, with 1 in Laramie and 1 in Century City in California. First Western Financial, Inc., was established in Colorado in 2002. It is located in Denver, Colorado.

Earnings Per Share

As for profitability, First Western Financial has a trailing twelve months EPS of $2.01.

PE Ratio

First Western Financial has a trailing twelve months price to earnings ratio of 12.87. Meaning,
the purchaser of the share is investing $12.87 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 9.26%.

5. ON Semiconductor (ON)

13.6% sales growth and 33.5% return on equity

ON Semiconductor Corporation offers intelligent power and sensing solutions around the world. Intelligent power technologies from ON Semiconductor Corporation enable electrification in the automotive industry. They allow for lighter, longer-ranged electric cars, fast charging systems and sustainable energy for solar strings, industrial power and storage. It operates in three segments: the Power Solutions Group and Advanced Solutions Groups, as well as the Intelligent Sensing Group. The company offers integrated, analog, module and discrete semiconductor products. These include power switching, conversion, signal conditioning and circuit protection. It also develops mixed-signal, analog, integrated power solutions, ASICs and radio frequency products for end-users. Government customers can get foundry services and custom design. It also develops image signal processors and complementary metal oxide semiconductor photo sensors. ON Semiconductor Corporation, based in Phoenix Arizona was founded in 1992.

Earnings Per Share

As for profitability, ON Semiconductor has a trailing twelve months EPS of $0.79.

PE Ratio

ON Semiconductor has a trailing twelve months price to earnings ratio of 82.34. Meaning,
the purchaser of the share is investing $82.34 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 33.5%.

Sales Growth

ON Semiconductor’s sales growth is 21.8% for the ongoing quarter and 13.6% for the next.

Growth Estimates Quarters

The company’s growth estimates for the present quarter and the next is 51.7% and 15.6%, respectively.

Revenue Growth

Year-on-year quarterly revenue growth grew by 31.3%, now sitting on 7.2B for the twelve trailing months.

6. Globus Medical (GMED)

11.2% sales growth and 9.28% return on equity

Globus Medical, Inc. is a medical device firm that focuses on developing and marketing implants to treat patients suffering from musculoskeletal conditions. The company’s spine portfolio offers a variety of surgical and implant options to address degenerative, abnormal, or tumor-related conditions in the spine, from the occiput through the sacrum. Products for orthopedic trauma include fracture plates, internal fixation system, external fixation systems, and intramedullary nail. The company also sells regenerative biologic products such as allografts, synthetic alternatives, and adjunctive treatment options that can be used with implant hardware to stabilize the spine. It also offers motion preservation technology, including dynamic stabilization and total disc replacement, interspinous distraction devices and interventional pain management to treat vertebral compress fractures. Further, the company offers expandable spacer products, which include RISE, RISE-L, CALIBER, CALIBER-L, ALTERA, ELSA, ELSA-ATP, SABLE, MAGNIFY, MAGNIFY-S, FORTIFY, and XPand; CREO thoracolumbar stabilization platform that offers instruments and implants for treating pathologies; CREO MIS and CREO MCS, options designed for less invasive surgery and minimal muscle disruption; CREO Derotation and CREO Rod Link Reducer systems, which help to streamline various derotation maneuvers for deformity correction; CREO Addition that provides a range of connectors; and CREO Fenestrated, a cement augmented pedicle screw system for patients with advanced stage tumors and limited life expectancy, as well as QUARTEX, an occipito-cervico-thoracic stabilization system. Globus Medical, Inc., was established in 2003. It is located in Audubon, Pennsylvania.

Earnings Per Share

As for profitability, Globus Medical has a trailing twelve months EPS of $1.48.

PE Ratio

Globus Medical has a trailing twelve months price to earnings ratio of 40.21. Meaning,
the purchaser of the share is investing $40.21 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 9.28%.

Sales Growth

Globus Medical’s sales growth is 10.4% for the ongoing quarter and 11.2% for the next.

Moving Average

Globus Medical’s worth is below its 50-day moving average of $61.05 and under its 200-day moving average of $65.47.

Yearly Top and Bottom Value

Globus Medical’s stock is valued at $59.51 at 01:22 EST, way below its 52-week high of $81.78 and way higher than its 52-week low of $52.60.

Growth Estimates Quarters

The company’s growth estimates for the present quarter and the next is 8% and 22.4%, respectively.

7. First Business Financial Services (FBIZ)

9% sales growth and 15.98% return on equity

First Business Financial Services, Inc. is the bank holding firm for First Business Bank. It provides services and products in commercial banking for entrepreneurs, small- and medium-sized business, executive, professional, and wealthy individuals. It offers deposit products such as time deposits and certificates of deposit as well as credit card options. The company also offers loan products such as commercial real estate loans and small-business administration loans. Direct financing leases are available. Consumer and other loans include home equity, second and first mortgages as well as personal loans to professional and executive clients. It offers equipment financing and commercial lending. First Business Financial Services, Inc. is located in Madison, Wisconsin.

Earnings Per Share

As for profitability, First Business Financial Services has a trailing twelve months EPS of $2.71.

PE Ratio

First Business Financial Services has a trailing twelve months price to earnings ratio of 12.52. Meaning,
the purchaser of the share is investing $12.52 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 15.98%.

Volume

Today’s last reported volume for First Business Financial Services is 4413 which is 81.95% below its average volume of 24456.

Sales Growth

First Business Financial Services’s sales growth for the next quarter is 9%.